MetaCap

Tenaya Therapeutics Inc. (TNYA)

NASDAQ: TNYAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.2866-0.0119 (-3.99%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TNYA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$65.32M
EPS (TTM)
-$0.48
52-week range
0.28 – 1.46
Day range
0.2827 – 0.3209
Volume / Avg
4.34M / 2.96M
Beta
—

52-week range

$0.28$1.46

TNYA stock today

On Nov 20, TNYA ended the session at $0.2866, shedding $0.0119 (3.99%), versus the S&P 500's 3.70% decline. At this level, TNYA sits near the bottom of its 52-week range of $0.28 to $1.46: 80.4% below the high, set on Dec 10, 2025 and 2.4% above the low. TNYA is down 59.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 76.7%.

Tenaya Therapeutics has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tenaya Therapeutics

Company profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Faraz Ali M.B.A.
Headquarters
South San Francisco, CA
Employees
70
IPO year
2021

Financial highlights

Full financials

Tenaya Therapeutics reported a net loss of $90.6 million, compared with a loss of $111.1 million a year earlier. Diluted earnings per share came in at -$0.59.

Tenaya Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-90.60M$-111.13M$-124.08M$-123.67M$-72.72M
EPS (diluted)$-0.59$-1.31$-1.68$-2.76$-4.10

Analyst forecast

Forecast

Consensus (6 analysts)

none

Avg. price target

$3.20+1016.54%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.08 vs $-0.10
Surprise
+20.00%

Tenaya Therapeutics peers

Health Care sector
TNYA peer companies
CompanyPrice% ChgMarket capCompare
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs TNYA
CRDFCardiff Oncology Inc.0.8528-4.46%$66.34Mvs TNYA
NMRANeumora Therapeutics Inc.0.3339-3.78%$63.01Mvs TNYA
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs TNYA
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs TNYA
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs TNYA
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs TNYA
BDTXBlack Diamond Therapeutics Inc.1.31-5.76%$75.28Mvs TNYA

Indexes, lists and sector

Tenaya Therapeutics stock FAQ

What is Tenaya Therapeutics's stock price today?

TNYA last traded at $0.2866 as of Nov 20, 4:00 PM EST, down 3.99% on the day. Prices are delayed at least 15 minutes.

Who is Tenaya Therapeutics's CEO?

Mr. Faraz Ali M.B.A. is the chief executive officer of Tenaya Therapeutics Inc., which has about 70 employees.

What is the TNYA 52-week high?

The 52-week high for TNYA is $1.46 and the 52-week low is $0.28. The stock is currently 80.4% below its high.

Compare TNYA